Stock Ratings / Health Care / CNTB / earnings

HYPD (38) CTOR (34) IBIO (23) GANX (41) ⌘ Pro Terminal →

Connect Biopharma Holdings Limited (CNTB) Next Earnings Date & Expected ±12.5% Move

$0.80 -3.97% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.79

Connect Biopharma Holdings Limited (CNTB) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $50.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CNTB Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CNTB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Connect Biopharma Holdings Limited (NASDAQ: CNTB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $0.80 (-3.97% 1D, market cap $50.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CNTB ranks #914 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CNTB compare to HYPD and CTOR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CNTB carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HYPD (Hyperion DeFi Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $49.7M) and CTOR (Citius Oncology Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $51.5M). Among the 5-stock peer group, CNTB leads on earnings multiple (N/A) while CNTB leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CNTB?

▼

Per CNTB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835268), Connect Biopharma Holdings Limited generated $64.0K in revenue (-99.8% YoY), -$55.5M in net income, and -$51.6M in free cash flow against $56.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.79 (-0.90%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-15% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CNTB)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (26/100 Composite)

🔍 WHY CNTB SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+8/20 pts (31% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 33.2 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.91-1.1% Next Q

Q2 (-2Q)

Grade E$0.90-5.6% Next Q

Q3 (-1Q)

Grade E$0.85-5.9% Next Q

Current

Grade E$0.80-10.5% Hist 90D α

Trajectory: E (34) → E (26)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CNTB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CNTB currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.33) and Max Pain ($0.84) forces dealer call-delta covering toward $4.01.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CNTB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CNTB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 26%NO 74%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.10 Expected Swing

MODEL EARNINGS SETUP GAUGE

CNTB Quantitative Pre-Earnings Setup: 26/100

Trailing EPS: $4.25 • YoY Revenue Growth: -65%

Model Bullish Setup (26/100)Model Risk Weight (74/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$64.0K	-$55.5M	-$51.6M	52%
FY 2024	2024-12-31	$26.0M	-$15.6M	-$24.4M	52%
FY 2023	2023-12-31	$0	-$62.1M	-$47.7M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CNTB)

✓Walkthrough of CNTB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CNTB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -67.74%📐 HORIZONTAL RANGE

2026-11-03O $0.83H $0.83L $0.80C $0.80VOL 2.50M

RES: $3.05SUP: $0.59SMA50: $1.33SMA200: $2.19

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CNTB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CNTB Butterfly Map → + Track CNTB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CNTB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CNTB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CNTB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CNTB)

Health Care Rank #914 of 1016 ⚔️ HYPD vs CNTB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CNTB vs. HYPD, CTOR, IBIO, GANX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Connect Biopharma Holdings Limited (CNTB) ranks #914 by composite RQD confidence (26/100, grade E) and #744 by equity capitalization ($50.5M). Within this direct 5-issuer industry benchmark cohort, CNTB leads on earnings valuation at N/A trailing P/E, while CNTB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GANX currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with CNTB at 26/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CNTB ACTIVE Connect Biopharma Holdings Limited	E	26/100	—	—	-35.0%	-3.97%	$50.5M	Benchmark Subject
HYPD Hyperion DeFi Inc.	D-	38/100	—	62.7%	-35.0%	-8.13%	$49.7M	/hypd-vs-cntb →
CTOR Citius Oncology Inc.	E	34/100	—	—	-35.0%	+4.63%	$51.5M	/ctor-vs-cntb →
IBIO iBio Inc.	E	23/100	—	—	-35.0%	-5.52%	$49.4M	/ibio-vs-cntb →
GANX Gain Therapeutics Inc.	D-	41/100	—	—	-35.0%	-5.04%	$49.3M	/ganx-vs-cntb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001835268

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Connect Biopharma Holdings Limited (CNTB) reported GAAP revenue of $64.0K (-99.8% vs. FY2024 revenue of $26.0M ) , GAAP net income of -$55.5M, operating cash flow of -$51.2M, and free cash flow of -$51.6M (-112.0% YoY). On the balance sheet, CNTB closed FY2025 with $56.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$64.0K	-$55.5M	-$51.2M	-$51.6M	$56.1M	—
FY2024 (FY)	2024-12-31	$26.0M	-$15.6M	-$23.6M	-$24.4M	$101.3M	—
FY2023 (FY)	2023-12-31	$0	-$62.1M	-$47.7M	-$47.7M	—	—

3. CNTB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CNTB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CNTB compare to HYPD and CTOR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CNTB?

Where is CNTB trading relative to its 50-day, 200-day, and 52-week technical levels?

CNTB last traded at $0.80 (-3.97% on volume of 2,503,785 shares), positioning the stock -39.85% below its 50-day simple moving average ($1.33) and -63.47% below its 200-day simple moving average ($2.19). Across its 52-week range of $0.73 to $3.82, CNTB sits at the 2.3% percentile with a 14-day RSI of 33.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.90).

CNTB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is CNTB's next earnings date?

Based on SEC filing cadence, Connect Biopharma Holdings Limited (CNTB)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is CNTB stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for CNTB, spanning a range between $1 and $0.9.

Direct Sub-Reports: CNTB RQD Cockpit CNTB 12M Forecast CNTB Earnings & Move CNTB Dividends & DRIP CNTB Insiders & 13F CNTB Whale Options CNTB Profit Sankey CNTB News & Why

ROARABLE RATING BRIEF • RQD 26/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CNTB — Connect Biopharma Holdings Limited: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:46:45Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CNTB scores 35 out of 100, earning a D- grade and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: Fundamental Cash Engine scores 7 / 20 (ROIC -35%; FCF yield 0%), indicating the business is not currently generating returns on capital or free cash flow. Whale 13F Flow scores 12 / 20 (institutional accumulation and options positioning), the strongest pillar but still below mid-range. Insider Conviction scores 3 / 20 (SEC Form 4 and Congressional PTR cluster flow), the weakest pillar, suggesting little insider-side conviction in the data. Macro Regime Fit scores 8 / 20 (Beta 1.0; sector sensitivity), a neutral-to-weak read on how the stock sits within its sector regime. Forensic Balance Sheet scores 5 / 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5), reflecting weak forensic financial health signals.

For a prospective investor evaluating the stock today, the upside case rests on the institutional flow pillar and the moderate leverage ratio, while the valuation tradeoff is severe: the stock trades at $0.8 with a $52.6M market cap against operating losses that the financial data shows exceed reported revenue in the most recent period. The ratings imply that a buyer is underwriting a turnaround in cash generation that the current filings do not yet demonstrate.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.1M	$-58.1M	$-55.5M	N/A	$-51.6M	$38.3M	N/A
FY 2024	$26.0M	$-22.5M	$-15.6M	N/A	$-24.4M	$78.2M	N/A
FY 2023	$0.0M	$-69.1M	$-62.1M	N/A	$-47.7M	N/A	N/A

Per the SEC financials and market data, operating margin and net margin are each -60%, gross margin is 0%, and ROIC is -35%, with FCF yield at 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Cash declined from $78.2M in FY 2024 to $38.3M in FY 2025 alongside continued negative free cash flow. Debt figures are not available in source data.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data.

Open Questions

What is the composition of FY 2025 revenue and why did it decline from $26.0M to $0.1M?
What is the cash runway given $38.3M in cash against a $-51.6M FCF in FY 2025?
What debt obligations exist, since debt is reported as N/A across all periods?
What drove the EPS gap, as EPS is N/A in every reported period?
What clinical, regulatory, or commercial catalysts are pending, given no news or catalysts are in source data?

CNTB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Connect Biopharma Holdings Limited (CNTB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CNTB Debate Forum (3) ↓

🟡 MARKET WIRE Benzinga • 6d ago

HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 price target.

Read Full Source ↗

🔴 RISK WATCH SeekingAlpha • 10d ago

Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript

Read Full Source ↗

🟢 CATALYST Yahoo • 11d ago

Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround

Connect Biopharma Holdings (CNTB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 14d ago

Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher

Connect Biopharma Holdings (CNTB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a tren

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 22d ago

Leerink Partners Assumes Connect Biopharma Hldgs at Outperform, Announces Price Target of $4

Leerink Partners analyst Will Soghikian assumes Connect Biopharma Hldgs (NASDAQ:CNTB) with a Outperform rating and announces Price Target of $4.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 30d ago

Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures

Connect Biopharma (NASDAQ:CNTB) reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients experiencing acute exacerbations of chronic obstructive pulmonary disease, or COPD. The company

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 33d ago

Connect Biopharma Reports Positive Phase 2 Rademikibart COPD Data, Plans FDA Talks on Phase 3 Program

Rademikibart significantly reduced treatment failure and new moderate-to-severe COPD exacerbations in the Seabreeze STAT study, while Connect Biopharma said it plans to discuss a Phase 3 registrational program with the F

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 33d ago

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) – – Rademikibart significantly reduced the rate of new moderate to severe COPD exacerbations thro

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CNTB Bull vs. Bear Conversation Board — What's Your Call at $0.80?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CNTB 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.70 (-12.5%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CNTB (D- • RQD 35/100) a Buy at $0.80?

Welcome to the CNTB (Connect Biopharma Holdings Limited) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.62 (-22.5%)

Spot @ $0.80

Pump the brakes on CNTB — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CNTB, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Connect Biopharma Holdings Limited expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.97 (+21.2%)

Spot @ $0.80

CNTB cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CNTB, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.80 (52-wk range $0.73 - $3.82), any beat on forward guidance forces shorts and underweight funds to chase.